Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | TGFBR1 | P36897 | 11/20 | 0.56 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.51 |
| ▸ | TDO2 | P48775 | 1/20 | 0.50 |
| ▸ | TGFBR2 | P37173 | 1/20 | 0.48 |
| ▸ | ABL2 | P42684 | 1/20 | 0.48 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.48 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.48 |
| ▸ | MAP3K20 | Q9NYL2 | 1/20 | 0.48 |
| ▸ | ILK | Q13418 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | CCR1 | P32246 | 1/20 | 0.46 |
| ▸ | CCR5 | P51681 | 1/20 | 0.46 |
| ▸ | CCR8 | P51685 | 1/20 | 0.46 |
| ▸ | METAP1 | P53582 | 1/20 | 0.46 |
| ▸ | BLM | P54132 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
| ▸ | DOHH | Q9BU89 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16535074 | 0.81 | NPY5R (0.57) | LMNATGFBR1MAPK14TGFBR2ABL2 | |
| SCHEMBL10413171 | 0.79 | TGFBR1 (0.77) | TGFBR1MAPK14TGFBR2ABL2CSNK1A1 | |
| SCHEMBL15314119 | 0.78 | AKT1 (0.56) | LMNATGFBR1MAPK14TGFBR2ABL2 | |
| SCHEMBL10921088 | 0.77 | TGFBR1 (0.51) | LMNATGFBR1MAPK14TDO2TGFBR2 | |
| SCHEMBL10513581 | 0.74 | TGFBR1 (0.51) | LMNATGFBR1MAPK14TDO2TGFBR2 | |
| SCHEMBL12265081 | 0.74 | TGFBR1 (0.51) | LMNATGFBR1MAPK14TGFBR2ABL2 | |
| SCHEMBL10513205 | 0.74 | TGFBR1 (0.51) | LMNATGFBR1MAPK14TGFBR2ABL2 | |
| SCHEMBL12313143 | 0.74 | TGFBR1 (0.51) | LMNATGFBR1MAPK14TGFBR2ABL2 | |
| SCHEMBL7264282 | 0.74 | TGFBR1 (0.59) | LMNATGFBR1MAPK14TGFBR2ABL2 | |
| SCHEMBL23294714 | 0.73 | TGFBR1 (0.54) | LMNATGFBR1MAPK14TGFBR2ABL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2755652-B1 | N-SUBSTITUTED HETEROCYCLYL CARBOXAMIDES | NOVARTIS AG (CH) | 2021-06-02 | — | — | EP | disclosed |
| US-10953012-B2 | Heterocyclic compounds for the inhibition of pask | BIOENERGENIX LLC (US) | 2021-03-23 | — | — | US | disclosed |
| US-10953012-B2 | Heterocyclic compounds for the inhibition of pask | BIOENERGENIX LLC (US) | 2021-03-23 | — | — | US | disclosed |
| US-9056867-B2 | N-substituted heterocyclyl carboxamides | NOVARTIS AG (CH) | 2015-06-16 | — | — | US | disclosed |
| US-20140323485-A1 | N-Substituted Heterocyclyl Carboxamides | NOVARTIS AG (CH) | 2014-10-30 | — | — | US | disclosed |
| EP-2755652-A1 | N-SUBSTITUTED HETEROCYCLYL CARBOXAMIDES | Novartis AG (CH) | 2014-07-23 | — | — | EP | disclosed |
| CN-103930109-A | N-substituted heterocyclyl carboxamides | NOVARTIS AG | 2014-07-16 | — | — | CN | disclosed |
| WO-2013038390-A1 | N-SUBSTITUTED HETEROCYCLYL CARBOXAMIDES | NOVARTIS AG (CH) | 2013-03-21 | — | — | WO | disclosed |
| WO-2012149157-A2 | HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK | BIOENERGENIX (US) | 2012-11-01 | — | — | WO | disclosed |
| WO-2012149157-A2 | HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK | BIOENERGENIX (US) | 2012-11-01 | — | — | WO | disclosed |
| US-20120277224-A1 | HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK | BIOENERGENIX (US) | 2012-11-01 | — | — | US | disclosed |
| US-20120277224-A1 | HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK | BIOENERGENIX (US) | 2012-11-01 | — | — | US | disclosed |
| US-20120277224-A1 | HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK | BIOENERGENIX (US) | 2012-11-01 | — | — | US | disclosed |
| US-7629294-B2 | Pyrazolopyrimidines | BAYER CROPSCIENCE LP (DE) | 2009-12-08 | — | — | US | disclosed |
| US-7629294-B2 | Pyrazolopyrimidines | BAYER CROPSCIENCE LP (DE) | 2009-12-08 | — | — | US | disclosed |
| US-7629294-B2 | Pyrazolopyrimidines | BAYER CROPSCIENCE LP (DE) | 2009-12-08 | — | — | US | disclosed |
| EP-1718652-A2 | PYRAZOLOPYRIMIDINES FOR COMBATTING UNWANTED MICROORGANISMS | Bayer CropScience Aktiengesellschaft (DE) | 2006-11-08 | — | — | EP | disclosed |
| WO-2005082907-A2 | PYRAZOLOPYRIMIDINES FOR CONTROLLING UNDESIRED MICROORGANISMS | BAYER CROPSCIENCE AG (DE) | 2005-09-09 | — | — | WO | disclosed |
| US-20050187224-A1 | Pyrazolopyrimidines | BAYER CROPSCIENCE AG (DE) | 2005-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120277224-A1 | HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK | PASK, PDXK, PANK2 | LMNA 1114/4885TGFBR1 4598/4885MAPK14 434/4885 |
| US-20140323485-A1 | N-Substituted Heterocyclyl Carboxamides | CFTR, AQP1, BDKRB1 | LMNA 2081/4885TGFBR1 1387/4885MAPK14 2919/4885 |
| US-10953012-B2 | Heterocyclic compounds for the inhibition of pask | PASK, PDXK, PANK2 | LMNA 1114/4885TGFBR1 4598/4885MAPK14 434/4885 |
| US-20050187224-A1 | Pyrazolopyrimidines | P2RX5, P2RX4, P2RX1 | LMNA 3788/4885TGFBR1 2746/4885MAPK14 4317/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.